Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 9/20 | 0.65 |
| ▸ | IKZF3 | Q9UKT9 | 3/20 | 0.65 |
| ▸ | IKZF1 | Q13422 | 3/20 | 0.65 |
| ▸ | TNF | P01375 | 2/20 | 0.65 |
| ▸ | IL1B | P01584 | 2/20 | 0.65 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.65 |
| ▸ | BRD4 | O60885 | 1/20 | 0.65 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.38 |
| ▸ | MAP1LC3B | Q9GZQ8 | 8/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3739220 | 0.99 | CRBN (0.63) | CRBNIKZF3IKZF1TNFIL1B | |
| SCHEMBL3750254 | 0.85 | CRBN (0.50) | CRBNIKZF3IKZF1TNFIL1B | |
| SCHEMBL25123796 | 0.84 | CRBN (0.59) | CRBNIKZF3IKZF1TNFIL1B | |
| SCHEMBL3743943 | 0.82 | CRBN (0.47) | CRBNIKZF3IKZF1TNFIL1B | |
| SCHEMBL3743004 | 0.81 | CRBN (0.46) | CRBNIKZF3IKZF1TNFIL1B | |
| SCHEMBL3746831 | 0.81 | CRBN (0.56) | CRBNIKZF3IKZF1TNFIL1B | |
| SCHEMBL19359461 | 0.81 | CRBN (0.77) | CRBNIKZF3IKZF1TNFIL1B | |
| SCHEMBL19359459 | 0.81 | CRBN (0.77) | CRBNIKZF3IKZF1TNFIL1B | |
| SCHEMBL3738089 | 0.79 | CRBN (0.47) | CRBNIKZF3IKZF1TNFIL1B | |
| Lenalidomide SCHEMBL10192650 | 0.79 | CRBN (1.00) | CRBNIKZF3IKZF1TNFIL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1341537-B1 | PHARMACEUTICALLY ACTIVE ISOINDOLINE DERIVATIVES | CELGENE CORP (US) | 2007-01-24 | — | — | EP | claimed |
| EP-1733726-A1 | Pharmaceutically active isoindoline derivatives | Celgene Corporation (US) | 2006-12-20 | — | — | EP | claimed |
| US-6762195-B2 | TREATING DISEASES MEDIATED BY TUMOR NECROSIS FACTOR; INHIBIT ANGIOGENESIS AND TREATMENT OF CANCER, INFLAMMATORY, AND AUTOIMMUNE DISEASES | CELGENE CORPORATION | 2004-07-13 | — | — | US | claimed |
| US-20040122052-A1 | Pharmaceutically active isoindoline derivatives | CELGENE CORPORATION | 2004-06-24 | — | — | US | claimed |
| EP-1341537-A4 | PHARMACEUTICALLY ACTIVE ISOINDOLINE DERIVATIVES | CELGENE CORP (US) | 2004-01-28 | — | — | EP | claimed |
| EP-1341537-A2 | PHARMACEUTICALLY ACTIVE ISOINDOLINE DERIVATIVES | CELGENE CORPORATION (US) | 2003-09-10 | — | — | EP | claimed |
| US-20030069428-A1 | Pharmaceutically active isoindoline derivatives | MULLER GEORGE | 2003-04-10 | — | — | US | claimed |
| WO-2002094180-A2 | PHARMACEUTICALLY ACTIVE ISOINDOLINE DERIVATIVES | CELGENE CORPORATION (US) | 2002-11-28 | — | — | WO | claimed |
| US-6458810-B1 | TREATMENT OF DISEASE STATES MEDIATED BY, TNF.ALPHA.. A TYPICAL EMBODIMENT IS TUMOR NECROSIS FACTOR FOR CANCER TREATMENT | CELGENE CORPORATION | 2002-10-01 | — | — | US | claimed |
| US-7834033-B2 | Methods for treating cancer using 3-[1,3dioxo-4-benzamidoisoindolin-2-yl]-2,6-dioxo-5-hydroxypiperidine | CELGENE CORPORATION (US) | 2010-11-16 | — | — | US | disclosed |
| EP-1733726-B1 | Pharmaceutically active isoindoline derivatives | CELGENE CORP (US) | 2009-06-03 | — | — | EP | disclosed |
| EP-1341537-B1 | PHARMACEUTICALLY ACTIVE ISOINDOLINE DERIVATIVES | CELGENE CORP (US) | 2007-01-24 | — | — | EP | disclosed |
| EP-1733726-A1 | Pharmaceutically active isoindoline derivatives | Celgene Corporation (US) | 2006-12-20 | — | — | EP | disclosed |
| US-20060069126-A1 | Pharmaceutically active isoindoline derivatives | CELGENE CORPORATION | 2006-03-30 | — | — | US | disclosed |
| US-20040122052-A1 | Pharmaceutically active isoindoline derivatives | CELGENE CORPORATION | 2004-06-24 | — | — | US | disclosed |
| EP-1341537-A4 | PHARMACEUTICALLY ACTIVE ISOINDOLINE DERIVATIVES | CELGENE CORP (US) | 2004-01-28 | — | — | EP | disclosed |
| EP-1341537-A2 | PHARMACEUTICALLY ACTIVE ISOINDOLINE DERIVATIVES | CELGENE CORPORATION (US) | 2003-09-10 | — | — | EP | disclosed |
| US-20030069428-A1 | Pharmaceutically active isoindoline derivatives | MULLER GEORGE | 2003-04-10 | — | — | US | disclosed |
| WO-2002094180-A2 | PHARMACEUTICALLY ACTIVE ISOINDOLINE DERIVATIVES | CELGENE CORPORATION (US) | 2002-11-28 | — | — | WO | disclosed |
| US-6458810-B1 | TREATMENT OF DISEASE STATES MEDIATED BY, TNF.ALPHA.. A TYPICAL EMBODIMENT IS TUMOR NECROSIS FACTOR FOR CANCER TREATMENT | CELGENE CORPORATION | 2002-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122052-A1 | Pharmaceutically active isoindoline derivatives | TNF, RELA, NFKBIA | CRBN 4232/4885IKZF3 109/4885IKZF1 41/4885 |
| US-20060069126-A1 | Pharmaceutically active isoindoline derivatives | TNF, RELA, NFKBIA | CRBN 4077/4885IKZF3 152/4885IKZF1 53/4885 |
| US-20030069428-A1 | Pharmaceutically active isoindoline derivatives | TNF, RELA, NFKBIA | CRBN 4232/4885IKZF3 109/4885IKZF1 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.